A U.S. group company will acquire IntraBio to expand global deployment of AQNEURSA and strengthen its rare disease portfolio. The purchase price is 2,000 million USD, with completion expected between November and December 2026. All shares of IntraBio will be acquired, and global rights to AQNEURSA will be obtained.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4507-20261005-01.pdf","jir_short_summary":"A U.S. group company will acquire IntraBio to expand global deployment of AQNEURSA and strengthen its rare disease portfolio. The purchase price is 2,000 million USD, with completion expected between November and December 2026. All shares of IntraBio will be acquired, and global rights to AQNEURSA will be obtained.","jir_summary":"### Overview and Background of the Transaction\nShionogi & Co., Ltd. has entered into an agreement for its U.S. group company, Shionogi Inc., to acquire IntraBio, Inc. The acquisition secures global rights to AQNEURSA and strengthens expertise in the rare disease field. By incorporating IntraBio\u2019s rare disease know-how, the company aims to accelerate development programs for fragile X syndrome, Jordan syndrome, Pompe disease, and other programs.\n\n### Financial and Business Impact and Outlook\nThe acquisition consideration is 2,000 million USD. Completion is anticipated between November and December 2026. AQNEURSA\u2019s label expansion for NPC and A-T is in progress, and the company plans to leverage the RADICAVA rare disease business foundation to expand supply of AQNEURSA. The impact on future consolidated results is under review; any matters requiring disclosure will be announced promptly.","jir_financial_highlights":"Acquisition Consideration: 2,000 million USD (Unknown)\nTarget Assets: Acquisition of global rights including intellectual property and commercialization rights for AQNEURSA and related compounds (Unknown)\nExpected Transaction Completion: November 2026\u2013December 2026 (expected) (Unknown)","jir_category":"","jir_hashtags":"#Shionogi, #USSubsidiaryAcquisition, #RareDiseaseStrategy","jir_key_figures":"Acquisition consideration: 2,000 million USD\nAcquisition of global exclusive rights to AQNEURSA and related compounds\nExpected transaction execution period: November 2026\u2013December 2026 (expected)","jir_meta_title":"Shionogi & Co., Ltd. to Acquire IntraBio as Wholly Owned Subsidiary\uff5c2,000 million USD, Completion Expected H2 2026","jir_meta_description":"Shionogi & Co., Ltd. has decided to make IntraBio a wholly owned subsidiary. The acquisition secures global rights to AQNEURSA and strengthens the rare disease business. Purchase price is 2,000 million USD, with completion expected between November and December 2026.","jir_og_title":"Shionogi & Co., Ltd. Announces Acquisition of IntraBio as Wholly Owned Subsidiary\uff5c2,000 million USD, Expected Completion in 2026","jir_og_description":"Announced acquisition to obtain global rights to AQNEURSA and strengthen the rare disease portfolio. Transaction expected to complete in the second half of 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-127278","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n